Novel Targeted Drug Delivery to the Cervix and Vagina by a Barrier Contraceptives Device: A Pilot Study for Proof the Concept
ESC Congress Library. Shihata A. May 4, 2016; 127014; A-188
Dr. Alfred Shihata
Dr. Alfred Shihata
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)


Background The vast majority of Sexually Transmitted Infections (STIs) and cervicitis are treated with drugs that come with potential systemic side effects. The few infections that are treated topically require gels or creams to be inserted into the vagina by traditional vaginal applicators. The vagina expels these gels and creams shortly after the insertion, rendering them less effective.




A) To test a barrier contraceptive device’s potential to deliver drugs topically for the treatment and prevention of STIs such as HPV, HIV, Gonorrhea, and Chlamydia.


B) To eliminate the need for destructive surgery on the cervix when treating HPV.


C) To enhance the safety and efficacy of topical treatments to the cervix and vagina.


Methods: We applied a stained vaginal gel over the cervix and vagina, using a vaginal applicator in 10 women. We applied the same stained gel with a barrier contraceptive device in 10 other women. We then compared the retention of the stained gel by photographing the cervix and vagina for the presence of the stained gel at 6, 12 and 24 hours after application.


Results: The stained gel was present over the cervix 24 hours after application with the contraceptive barrier device. It was absent after 6 hours when applied with the vaginal applicator.


Conclusion: This pilot study has demonstrated that gels or creams inserted into the vagina using the barrier contraceptive device have much better retention. Thus, more prolonged contact with an offending pathogenic agent would be anticipated.


This study may lead to a topical method for the prevention and treatment of STIs, including HPV and HIV infections. Topical treatment may also lead to better safety and higher efficacy than systemic treatment.

    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings